SkyePharma Signs Development Contract With Amgen
Tuesday April 4, 8:16 am Eastern Time
Company Press Release
SOURCE: SkyePharma PLC
LONDON, April 4 /PRNewswire/ -- SkyePharma PLC (Nasdaq: SKYE; LSE: SKP), announced today that it has signed a development contract with Amgen Inc. (Nasdaq: AMGN - news) of USA. The items of the contract are confidential, however SkyePharma confirmed that it was utilizing its DepoFoam sustained release injectable delivery system with an undisclosed Amgen product. Under the first phase of the agreement Amgen will complete its evaluation of the DepoFoam technology for use with the Amgen product.
Michael Ashton, Chief Executive Officer of SkyePharma said: "We continue to be delighted with the progress of DepoFoam and to be working with Amgen -- one of the acknowledged world leaders in Biotechnology. This contract marks a significant development milestone for DepoFoam".
SkyePharma PLC, one of the world's leading drug delivery companies, develops and manufactures advanced drug delivery solutions. Its technologies include oral controlled release, injectable, inhalation and topical systems. For company information, visit SkyePharma on the World Wide Web at skyepharma.com.
This press release may contain forward-looking statements regarding SkyePharma PLC. Actual results may differ materially from those described in the press release as a result of a number of factors, including but not limited to the following: There can be no assurance that any product in the SkyePharma product pipeline will be successfully developed or manufactured, or that final results of human clinical trials will result in the regulatory approvals required to market products, or that final regulatory approval will be received in a timely manner, if at all, or that patient and physician acceptance of these products will be achieved. The Company undertakes no obligation to revise or update any such forward-looking statement to reflect events or circumstances after the date of this release.
SOURCE: SkyePharma PLC |
